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http://dx.doi.org/10.1016/j.asjsur.20Summary Breast cancer is one of the most common origins of metastatic lesions in the
central nervous system. Many patients with a breast cancer and concurrent brain tumor(s)
were diagnosed to have a metastatic lesion or lesions in the brain, based exclusively on their
image findings without further pathologic verification, and received radiotherapy alone there-
after. It is, however, possible that a different pathology such as primary brain malignancy,
which actually warrants a specific treatment modality, may occur in such patients with an
already known malignancy. We, herein, reported a 61-year-old female patient who suffered
from an anaplastic oligodendroglioma 1 year after her diagnosis of breast cancer. Demographic
data, characteristic imaging findings, treatment, and outcome of the patient were discussed.
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Breast cancer is one of the most common origins of the
metastatic lesions in the central nervous system (CNS). As
estimated, approximately 10e15% of breast cancer patients
suffer from the CNS metastatic lesion(s) throughout the
course of treatment.1 Many patients with a breast cancerby Elsevier Taiwan LLC. All rights reserved.
High-grade glioma in a patient with breast cancer 163and concurrent brain tumor(s), however, do not receive
a surgical extirpation or biopsy for the CNS lesions, because
characteristic radiological findings such as a ring-like
enhancing lesion or multiple lesions with peritumoral
edema in the computed tomography (CT) and magnetic
resonance imaging (MRI) often have made a putative diag-
nosis of malignant metastatic lesion or lesions. These
patients are often treated with whole-brain radiotherapy
(WBRT) to the brain plus systemic chemotherapy for local
tumoral control, because most patients with metastatic
lesions, especially those with multiple small lesions (less
than 2 2 2 cm3) that originated from breast cancer,
response well to the radiation treatment.1,2 It is, however,
possible that primary brain malignant gliomas, although
relatively rare in incidence, may develop in patients with
a systemic malignancy, and such patients actually need
a treatment modality already developed and tailored for
primary CNS malignancy.3 We reported a female patient
who suffered from an anaplastic oligodendroglioma 1 year
apart after her diagnosis of breast cancer. Demographic
data, characteristic imaging findings, tailored treatment,
and final outcome of the patient were discussed.2. Case report
A 61-year-old woman was diagnosed to have a right-sided
invasive ductal carcinoma (T2N2M0, stage IIIA) and left-
sided ductal carcinoma in situ 1 year prior to her neuro-
logic evaluation. She had no family history of breast cancer,
and had undergone right-side modified radical mastectomy
and left-side total mastectomy thereafter. The tumor was
confirmed to be an adenocarcinoma that was strongly
positive for estrogen and progesterone receptors but was
negatively stained for human epidermal growth factor
receptor-2 (HER2). The patient was further treated with
local radiotherapy (50 Gy for right chest wall and 50 Gy for
right supraclavicular lymph nodes) and chemotherapy withFigure 1 Magnetic resonance imaging of the patient’s brain. (A)
a large left-sided parieto-occipital lesion, located at the subcortica
two concurrent small lesions in the ipsilateral lateral ventricle wall
lesion shows compression of the left lateral ventricle and extensiocyclophosphamide, doxorubicin, and paclitaxel, without
notable adverse effects.
The patient experienced progressive recent and remote
memory impairment and cognitive dysfunction 1 year after
her diagnosis of breast cancer. She was also found to have
mild weakness (motor gradeZ 4þ/5) of the right upper and
lower limbs. Cranial functions and other neurologic exam-
inations were unremarkable. Further CT and MRI examina-
tions of the brain demonstrated that the patient had
multiple brain lesions, including a large (4 4 5 cm3 in
size) brain tumor located at left parieto-occipital subcor-
tical regions extending into the ipsilateral splenium of the
corpus callosum, and two other small, but apart, lesions in
the lateral ventricle wall and the parietal cortex of the
ipsilateral brain (Fig. 1). The patient was diagnosed to have
a multifoci primary brain malignancy rather than secondary
metastases, because the largest brain lesion was relatively
infiltrative and deeply invasive to the corpus callosum. She
subsequently underwent a craniotomy for gross total
resection of the largest brain lesion. Pathologic examina-
tion demonstrated the tumor to be an anaplastic oligo-
dendroglioma with plenty of cells having hyperchromatic,
pleomorphic nuclei and abundant pale eosinophilic cyto-
plasm, and with vascular proliferation (Fig. 2A). Further
immunohistochemical examinations showed that the tumor
was strongly positive for glial fibrillary acidic protein (GFAP)
but was negative for cytokeratin staining (Fig. 2B and 2C).
Moreover, the Ki-67 labeling index was found to be
approximately 40% (Fig. 2D), indicating a relatively high
mitotic activity. Furthermore, the methylation-sensitive
polymerase chain reaction (PCR) of the tumoral tissues
demonstrated the O6-methylguanine-DNA methyltransfer-
ase (MGMT) promoter of the tumor to be a methylated one
(Fig. 3A). Capillary electropherograms of PCR products
resulting from amplification of microsatellite loci on chro-
mosomes 1p and 19q revealed that the tumor samples
contained 1p/19q codeletion (Fig. 3B). The patient then
received external beam radiotherapy up to 60 Gy with
concurrent daily temozolomide treatment (75 mg/kg),Axial T1-weighted image with gadolinium enhancement shows
l region but extending into the ipsilateral corpus callosum, and
and parietal cortex (arrows). (B) Coronal section of the largest
n into the corpus callosum.
Figure 2 (A) Hematoxylin and eosin staining shows plenty of tumor cells with hyperchromatic, pleomorphic nuclei and abundant
pale eosinophilic cytoplasm, and vascular proliferation. Immunohistochemical examinations showed that the tumor was (B)
negative for cytokeratin staining but (C) strongly positive for glial fibrillary acidic protein. (D) The Ki-67 labeling index is about 40%.
164 C.-C. Chang et al.followed by standard temozolomide monotherapy (200 mg/
kg) for the subsequent 12 months. The patient tolerated
the treatment well and made an uneventful recovery. Her
Karnofsky performance scale was improved from a score of
60 to that of 70 after the neurosurgical treatment. In
addition, she remained progression free and did not have
notable intracranial recurrence up to 24 months after her
brain surgery (Fig. 3C).3. Discussion
Primary brain tumors may occur in patients who have
systemic malignancies, especially in the era with improved
surgical techniques for tumoral extirpation, followed by
well-developed radiotherapy and chemotherapy, or even
target therapy.5,6 In a retrospective study, Maluf et al6
have identified 21 patients with a histologic diagnosis of
concurrent high-grade glioma after a prior diagnosis of
a solid or hematological malignancy. In particular, breast
cancer is the most common cancer in women. It has been
estimated that approximately 10e15% of breast cancer
patients will suffer from the CNS metastatic lesion(s)
throughout the course of the treatment.1 In contrast, an
annual incidence of concurrent primary brain malignancy in
patients with other systemic cancers can be expected to be
much less than 1 per million in the general population,
solely based on the annual incidence rates of 10e15 cases
per 100,000 who develop primary brain tumors.7 Thus, it is
evident that in patients with a known systemic malignancy
such as breast cancer, the incidence of metastatic brainlesion(s) is far more prevalent than that of the concurrent
primary brain malignancy.
It is noteworthy that in most breast cancer patients,
a diagnosis of CNS metastases is often determined by either
contrast-enhanced CT or MRI of the brain alone. Arslan
et al1 have retrospectively collected 259 breast cancer
patients with CNS metastases and have found that only
32 patients (13%) underwent surgery for pathological veri-
fication of their CNS metastases. Kim et al2 also reported
a retrospective study including 400 breast cancer patients
with CNS metastases and have noted that only five
patients (1.3%) had underwent surgical intervention for
pathological confirmation. However, it is clinically essential
to differentiate between primary and metastatic intrace-
rebral lesions in patients with systemic malignancies, thus
offering appropriate treatment protocols. Different
surgical planning and therapeutic modalities between the
two disease entities may affect the final outcome of
patients greatly, when an inappropriate diagnosis is made
solely based on the imaging diagnosis.3 In the study of Maluf
et al, it has been observed that four patients were mis-
diagnosed as having brain metastases. These patients had
received WBRT alone and, thus, the surgical intervention
and appropriate chemotherapy tailored for primary CNS
malignant gliomas were much delayed.3
Distinguishing the high-grade glioma from brain metas-
tases solely on the basis of contrast-enhanced CT or MRI is
virtually difficult, because many cases of these two disease
entities may have similar imaging characteristics.4 Server
et al4 have reported the use of 3 T MRI with vascular
permeability and vascular perfusion (relative cerebral
Figure 3 (A) Examinations for MGMT promoter of the tumor proved the tumor sample to be a methylated one. (B) Amplification
of microsatellite loci on chromosomes 1p and 19q revealed that the tumor samples contained 1p/19q codeletion. Follow-up MRI
examinations of the brain were taken at 24 months postoperatively. (C) Axial and coronal T1-weighted images with gadolinium
enhancement as well as T2-FLAIR revealed no notable recurrence of the tumors. MZmethylated MGMT promoters; MGMTZO6-
methylguanine-DNA methyltransferase; UZ unmethylated MGMT promoters.
High-grade glioma in a patient with breast cancer 165blood volume and blood flow) imaging methods to distin-
guish high-grade gliomas from metastases. They, however,
have noted that the specificity and accuracy were actually
inconsistent for most cases. However, some MRI findings
might provide clues to differentiate between a primary
brain malignancy and a brain metastasis. It has been
demonstrated that an infiltrative lesion involving the corpus
callosum, lesions involving deep white matter structures,
and extensive infiltration involving both gray and white
matter may provide more possibility to suggest a glioma
rather than a metastatic lesion.5 In our case, the infiltrative
tumor involving the corpus callosum raised the suspicion
of a primary brain tumor, which was subsequently
confirmed after surgical resection and histopathologic
examinations. Thus, this patient could receive a treatment
modality tailed for high-grade glioma, and has made
a favorable disease control up to 24 months post-
operatively. In the patient, the nature of the anaplastic
oligodendroglioma with a combination of methylated MGMT
promoter and 1p/19q codeletion has certainly made thetumor more amenable to chemotherapy, with a complete
response following surgical extirpation.8,9
In this case, we could not exclude completely the
possibility that the other two small nodules observed in the
ipsilateral contiguous cortical and ventricular regions, as
seen in Fig. 1, were actually metastatic lesions originated
from her breast cancer. In a follow-up period of 2 years, the
patient, however, did not have notable metastatic lesions
from her breast cancer. A high mitotic activity of the
anaplastic oligodendroglioma, as evidenced by 40% of the
Ki-67 labeling index, also suggested a relatively high risk for
developing early intracranial seeding of the anaplastic oli-
godendroglioma along the white matter and CSF pathways.
Alternatively, it was also likely that this multifocal tumor
had phenotypes derived from different progenitor cells of
tumors (polyclonal origin). A favorable outcome observed
with the patient, however, support that the presence of
intracranial tumor dissemination on initial diagnosis does
not, in itself, preclude aggressive treatment for high-grade
glioma if a patient is otherwise well.
166 C.-C. Chang et al.In summary, in patients with systemic malignancies
and concurrent infiltrative brain lesion(s), primary brain
malignancy should be included in the differential diagnosis,
in addition to secondary metastases. We emphasize that
surgical intervention for histopathologic examinations is
needed for such patients, especially when there are char-
acteristic MRI findings suggestive of gliomas rather than
metastases.
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